Zenas BioPharma (ZBIO) is back in focus after second quarter 2026 results showed revenue of US$1 million alongside a net loss of US$111.46 million, paired with several senior leadership changes.

At a share price of US$31.91, Zenas BioPharma has seen a 90 day share price return of 63.14%, while the year to date share price return is down 7.51% and the 1 year total shareholder return is 101.32%. This suggests recent momentum has picked up even as the latest earnings and leadership changes give investors more to weigh.

If you are looking beyond Zenas BioPharma and want ideas across the broader biotech and tech enabled drug development space, it can be useful to scan other healthcare focused AI opportunities such as those in our 42 healthcare AI stocks

After such a sharp move in Zenas BioPharma on the back of shrinking revenue and a wider loss, the key tension is clear: Is most of the upside already behind the stock, or does the current price still leave room ahead based on valuation?

Preferred price to book of 8.4x: Is it justified?

On roughly $1 million of revenue and a market cap of about $2.0b, Zenas BioPharma currently trades on a P/B of 8.4x compared with 2.5x for the broader US Biotechs industry. That is a rich starting point for a company that remains loss making and is not expected to reach profitability over the next three years.

The P/B ratio compares the company’s market value to its net assets on the balance sheet. For early stage biopharma stocks like Zenas BioPharma that are still in the clinical stage and unprofitable, investors often focus on P/B because traditional earnings based metrics such as P/E are not meaningful. A higher P/B usually reflects expectations that the current pipeline and future revenue potential will justify paying well above the current accounting book value.

Relative to the wider US Biotechs industry average of 2.5x, Zenas BioPharma’s 8.4x P/B suggests investors are paying a substantial premium. However, compared with a peer group average P/B of 10.6x, the stock sits at a lower level, which indicates the market is assigning it somewhat less value than those peers on this measure. With no fair ratio available, there is no additional regression based anchor for where the P/B could settle if sentiment or assumptions changed.

Result: Price-to-book of 8.4x

However, Zenas BioPharma still faces material risks around ongoing net losses of US$484.384 million and clinical execution on its lead immunology pipeline, which could challenge today’s premium P/B ratio.

Next Steps

Given the mixed picture for Zenas BioPharma, you may want to move quickly and review the underlying data yourself to decide how the risk and reward trade off stacks up. To weigh both sides of the story in one place, start with the 1 key reward and 3 important warning signs

Looking for more investment ideas beyond Zenas BioPharma?

If Zenas BioPharma has sharpened your focus on where capital goes next, it is worth broadening your watchlist with a few targeted, data driven stock ideas.

• Target stability first and put capital to work in companies that score well on resilience through our 79 resilient stocks with low risk scores.
• Spot potential mispricings and compare Zenas BioPharma with a wider set of value candidates by reviewing our 50 high quality undervalued stocks.
• Hunt for underfollowed opportunities before the crowd pays attention by scanning our screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.